Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control

Executive Summary

Now that FDA has unveiled what it expects in a Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, sponsors will be scrambling to write the REMS for their individual products and put together the shared components and implementation system envisioned by the agency.

You may also be interested in...



FDA Standardizing REMS Re-Enrollment Procedures

Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.

Opioid Class-Wide REMS May Launch Without Element To Monitor Prescribing

All metrics for assessing the effectiveness of the Risk Evaluation and Mitigation Strategy for long-acting/extended release opioids may not be in place when FDA approves REMS for individual products.

Opioid Class-Wide REMS May Launch Without Element To Monitor Prescribing

All metrics for assessing the effectiveness of the Risk Evaluation and Mitigation Strategy for long-acting/extended release opioids may not be in place when FDA approves REMS for individual products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel